Geo News
Community curated by people like you
LatestAICryptoHealthWorld AffairsUS Politics

Non-small cell lung cancer stories

Nov 5, 2026

FDA grants J&J accelerated approval for head and neck cancer treatment

The FDA granted accelerated approval to Johnson & Johnson's treatment for patients with advanced head and neck cancer whose disease has worsened after prior therapy.

Nov 5, 2026·2 sources
00
Sep 21, 2026

Ivonescimab extends survival vs pembrolizumab in PD-L1+ advanced NSCLC trial

First-line ivonescimab significantly prolonged overall survival compared with pembrolizumab in patients with PD-L1-positive advanced non-small cell lung cancer, according to updated analysis from a clinical trial.

Sep 21, 2026·2 sources
00
Sep 13, 2026

Multimodal AI model outperforms established biomarkers for immunotherapy in lung cancer

A large international real-world study found that a multimodal explainable AI decision support tool outperformed established biomarkers for predicting immunotherapy outcomes in non-small cell lung cancer and improved physician decision-making.

Sep 13, 2026·2 sources
00

Top claims

  • ▪Intravenously infused Rybrevant received its initial FDA approval in 2021 for treating non-small cell lung cancers harboring an EGFR mutation
  • ▪Rybrevant is a bispecific antibody designed to block EGFR and MET, two receptors overexpressed in certain cancers, to overcome single-target treatment resistance
  • ▪For the first nine months of 2026, Johnson & Johnson reported $866 million in global Rybrevant/Lazcluze sales, representing a 67.4% year-over-year increase

Topics

FDA drug approvalCancer & OncologyAccelerated approval pathwaysTargeted cancer therapyDrug Policy, Pricing & ApprovalBiologic therapiesClinical trialsAdvanced drug delivery formulationsImmunotherapyDrug Approval and Clinical TrialsClinical evaluationCancer treatment breakthroughsClinical Trial Design & EvaluationCancer treatmentMultimodal modelsAI in healthcareClinical decision supportAI interpretability

Related entities

RybrevantHuman PapillomavirusPembrolizumabLung cancerImmunotherapy